The Pertussis Serological Potency Test. Collaborative study to evaluatereplacement of the Mouse Protection Test.
The Pertussis Serological Potency Test (PSPT)--based on in vitro assessment of the humoral immune response against Bordetella pertussis--was developed as an alternative for the Mouse Protection Test (MPT). A small-scale collaborative study was carried out in five laboratories to evaluate the relevance and reliability of the PSPT. The study has been divided into three separate phases, each with its own objective. A pilot-phase study of the antibody detection assay, the 18323-whole cell ELISA (WCE), was included for training purposes. Significant differences in absorbance and antibody concentrations between the laboratories were found. In the Phase I study, the intra-assay, inter-assay and inter-laboratory precisions of the 18323-WCE were assessed. Although a precision of less than 20% was not always established and significant differences in antibody concentrations were found at random throughout the Phase I study, the ranking of the antibody concentrations corresponded well between the laboratories and should warrant a reliable potency estimation of whole cell vaccines (WCV's) in the PSPT. Phase II was a comparative study of the PSPT and the MPT to evaluate the implementation of the PSPT, to demonstrate correlation and to compare the reproducibility and reliability of both tests. The mean antibody concentrations per vaccine dose in the PSPT and the survival of mice in the MPT differed significantly within and between the laboratories. Nevertheless, the potencies of the vaccines under test estimated in both test models did not differ significantly (P>0.05). The PSPT and MPT correlated well in chi2-test of homogeneity within and between the laboratories. The potencies were similar (overall ratio=0.877), but the PSPT is more reproducible and reduces the chance of re-testing due to the smaller 95% confidence intervals. We have demonstrated that the PSPT is a valid model to estimate the potencies of pertussis WCV's from different manufacturers. Moreover, the 18323-WCE is easy to carry out and the intra-assay precision and antibody ranking warrants a reliable potency testing of pertussis WCV's in the PSPT.
van der Ark
A
A
National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.
van Straaten-van de Kappelle
I
I
Olander
R M
RM
Enssle
K
K
Jadhav
S
S
van de Donk
H
H
Hendriksen
C
C
D000826:Animal Testing Alternatives; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D001681:Biological Assay; D001886:Bordetella pertussis / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D005260:Female; D008297:Male; D051379:Mice; D010567:Pertussis Vaccine / Q000276:immunology / Q000592:standards*; D010865:Pilot Projects; D011786:Quality Control; D011897:Random Allocation; D015203:Reproducibility of Results; D012449:Safety; D014917:Whooping Cough / Q000517:prevention & control; D014944:World Health Organization
D000907:Antibodies, Bacterial; D010567:Pertussis Vaccine